Novel therapies for inherited IRDs have rapidly emerged, particularly since clinical trials for LCA caused by RPE65 variants led to the first FDA-approved in vivo gene therapy [44]. The gene discussed is RPE65; the disease is respiratory distress syndrome in premature infants.